Onyx Therapeutics, Inc. v. InnoPharma Inc.
1:16-cv-01036
Overview
Parties
Defendant
InnoPharma Inc. Operating Company
Represented By
4 Attorneys ListedPhillips, Goldman, McLaughlin & Hall, P.A.
Phillips, Goldman, McLaughlin & Hall, P.A., 1200 North Broom Street
Phillips, McLaughlin & Hall, P.A.
Phillips, McLaughlin & Hall, P.A., 1200 N. Broom St
Plaintiff
Onyx Therapeutics, Inc. Operating Company
Represented By
6 Attorneys ListedMorris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
O'Melveny & Myers LLP
7 Times Square, Times Square Tower, New York, NY 10036
Morris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360Β° Radar 4 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| πΊπΈ United States | US 7,417,042 B2 Asserted | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 59,940,104 P | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 61,000,104 P | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 7,232,818 B2 | US Continuation / Sibling | View Official Patent → |
Onyx Therapeutics, Inc. v. Sagent Pharmaceuticals, Inc.
Patents Involved
There are 3 patents involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US7417042
Compounds for enzyme inhibition
|
Filed: 2005-08-08
Issued: 2008-08-26
|
Active (0.8 yrs remaining)
+765d PTA
Expires: 2027-09-12
|
|
|
US7737112
Composition for enzyme inhibition
|
Filed: 2005-12-07
Issued: 2010-06-15
|
Active (1.1 yrs remaining)
+742d PTA
Expires: 2027-12-19
|
|
|
US8207297
Compounds for enzyme inhibition
|
Filed: 2011-12-22
Issued: 2012-06-26
|
Active (5.1 yrs remaining)
Expires: 2031-12-22
|
Patent Enforceability & Injunction Risk Assessment
Active Threat β Patent is within enforceable statutory term. Patentee retains legal standing to seek permanent injunctive relief and exclusion orders.
High PTA (+765 days) / Cellect Scrutiny β Over 765 days of PTA awarded. Susceptible to In re Cellect double patenting invalidation if continuation patents in the same family expire earlier.
Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).
Procedural Motions & Interlocutory Orders
Total Motions
7
Dispositive
0
Granted
0
Denied
0
Pending / Review
4
Motions by Category
Key Dispositive Motions & Rulings